8-K: Dentsply Sirona Reports Mixed 2023 Results, Provides Cautious 2024 Outlook and Increases Dividend

Dentsply Sirona's full year 2023 results show a slight increase in net sales, a net loss, and a 14% increase in the quarterly dividend, with a flat to modest growth outlook for 2024.

Summary

• Dentsply Sirona announced its fourth quarter and full year 2023 financial results on February 29, 2024.
• Full year 2023 net sales reached $3,965 million, a 1.1% increase compared to 2022, with organic sales growth of 2.2%.
• The company reported a GAAP net loss of $132 million, or $0.62 per share, for the full year 2023, compared to a net loss of $950 million, or $4.41 per share in 2022.
• Adjusted earnings per diluted share for 2023 were $1.83, down from $2.09 in 2022.
• Fourth quarter net sales were $1,012 million, a 2.9% increase, with organic sales growth of 1.9%.
• Q4 GAAP net income was $67 million, or $0.32 per share, compared to a net loss of $15 million, or $0.07 per share in Q4 2022.
• Adjusted earnings per diluted share for Q4 were $0.44, compared to $0.46 in Q4 2022.
• The company's 2024 outlook projects organic sales to be flat to up 1.5% and adjusted EPS between $2.00 and $2.10.
• The Board of Directors approved a 14% increase in the quarterly dividend to $0.16 per share, payable on April 12, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While there are positive aspects like increased sales and a dividend hike, the net loss and decreased adjusted EPS temper the overall outlook. The company is in a transitional phase with some improvements but also ongoing challenges.

Positives

• Full year net sales showed a slight increase of 1.1% and organic sales increased by 2.2%.
• The net loss for the full year 2023 was significantly reduced compared to 2022, from $950 million to $132 million.
• Fourth quarter net sales increased by 2.9% and organic sales increased by 1.9%.
• The company returned $416 million to shareholders in 2023 through dividends and share repurchases.
• The quarterly dividend was increased by 14%, demonstrating a commitment to returning cash to shareholders.
• Operating cash flow in the fourth quarter of 2023 was $160 million, compared to $142 million in the prior year.

Negatives

• The company reported a GAAP net loss of $132 million for the full year 2023.
• Adjusted EPS for 2023 decreased to $1.83 from $2.09 in 2022.
• Adjusted EPS for Q4 2023 was $0.44, down from $0.46 in Q4 2022.
• Full year 2023 operating cash flow was $377 million, as compared to $517 million in the prior year.
• The Connected Technology Solutions segment experienced a decline in net sales and organic sales for both Q4 and the full year.

Risks

• The company faces risks associated with a competitive marketplace, requiring product differentiation.
• Failure to realize assumptions and projections could lead to additional impairment charges.
• Changes to distribution channels and ineffective inventory management by distributors pose risks.
• The company's ability to control costs and realize benefits from restructuring efforts is uncertain.
• The company must adapt to changes and trends within the rapidly changing dental industry.
• The company's forward-looking statements are subject to numerous assumptions, risks and uncertainties.

Future Outlook

The company anticipates flat to 1.5% organic sales growth and adjusted EPS between $2.00 and $2.10 for the full year 2024.

Management Comments

• Simon Campion, President and Chief Executive Officer, stated that the company delivered on its outlook with three of four segments posting year-over-year growth in the fourth quarter and full year 2023.
• Simon Campion also mentioned that Dentsply Sirona's transformation is taking shape and that 2024 is expected to be an inflection point for improved profitability and adjusted earnings per share growth.
• Management maintains its conviction that the company is on the right path to deliver meaningful value over the long term.

Industry Context

The dental industry is competitive, and Dentsply Sirona's results reflect the challenges of maintaining profitability while adapting to changing market trends. The company's focus on restructuring and cost control is in line with industry efforts to improve efficiency and profitability.

Comparison to Industry Standards

• Dentsply Sirona's organic sales growth of 2.2% for the full year is moderate compared to some high-growth medical device companies, but is reasonable given the current economic climate.
• Companies like Align Technology (ALGN) in the orthodontic space have shown higher growth rates, but Dentsply Sirona's diversified portfolio provides some stability.
• The adjusted EPS of $1.83 for the year is below some of its peers, indicating room for improvement in operational efficiency and cost management.
• The 14% dividend increase is a positive sign for investors, suggesting confidence in future cash flow generation, and is higher than many of its peers in the medical device sector.

Stakeholder Impact

• Shareholders will benefit from the increased dividend and share repurchases.
• Employees may be affected by ongoing restructuring efforts.
• Customers will continue to receive dental products and technologies from the company.
• Suppliers will continue to engage with the company as a major player in the dental industry.
• Creditors will be monitoring the company's financial performance and debt levels.

Next Steps

• The company will continue to focus on its transformation plan to improve profitability.
• Management will host an investor conference call and live webcast on February 29, 2024, to discuss the results.
• The company will pay the increased quarterly dividend on April 12, 2024.

Key Dates

Keywords

Dentsply Sirona, Dental Products, Financial Results, Net Sales, Earnings Per Share, Dividend, Organic Sales, Adjusted EBITDA, Restructuring, Dental Technology